Do enthalpy and entropy distinguish first in class from best in class?

Drug Discovery Today

Volumn 13, Issue 19-20, 2008, Pages 869-874

  Freire, Ernesto ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; ATORVASTATIN; CERIVASTATIN; DARUNAVIR; FLUINDOSTATIN; INDINAVIR; LOPINAVIR; NELFINAVIR; PRAVASTATIN; RITONAVIR; ROSUVASTATIN; SAQUINAVIR; TIPRANAVIR;

BINDING AFFINITY; DRUG BINDING; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENTHALPY; ENTROPY; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DESIGN; ENTROPY; HUMANS; HYDROGEN BONDING; LIGANDS; PHARMACEUTICAL PREPARATIONS; RECEPTORS, DRUG; THERMODYNAMICS;

EID: 52049123291     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.07.005     Document Type: Review

References (30)

1. Ohtaka H., and Freire E. Adaptive inhibitors of the HIV-1 protease. Progr. Biophys. Mol. Biol. 88 (2005) 193-208
2. Carbonell T., and Freire E. Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry 44 (2005) 11741-11748
3. Ruben A.J., et al. Overcoming roadblocks in lead optimization: a thermodynamic perspective. Chem. Biol. Drug Des. 67 (2006) 2-4
4. Sarver R.W., et al. Binding thermodynamics of substituted diaminopyrimidine renin inhibitors. Anal. Biochem. 360 (2007) 30-40
5. Chaires J.B. Calorimetry and thermodynamics in drug design. Ann. Rev. Biophys. 37 (2008) 135-151
6. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44 (2000) 235-249
7. Lipinski, C.A. (2003) Physicochemical properties and the discovery of orally active drugs: technical and people issues. In Molecular Informatics Confronting Complexity. Proceedings of the Beilstein Institute Workshop, 13th-16th May 2002 (Kettner, M.G.H.a.C., ed.), pp. 59-78, Logos Verlag
8. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
9. Velazquez-Campoy A., et al. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch. Biochem. Biophys. 390 (2001) 169-175
10. Freire E. Isothermal titration calorimetry: controlling binding forces in lead optimization. Drug Discov. Today 1 (2005) 295-299
11. Velazquez-Campoy A., et al. Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor. Protein Sci. 9 (2000) 1801-1809
12. Cabani S., et al. Group contributions to the thermodynamic properties of non-ionic organic solutes in dilute aqueous solution. J. Solut. Chem. 10 (1981) 563-595
13. Sharp K.A., et al. Extracting hydrophobic free energies from experimental data: relationship to protein folding and theoretical models. Biochemistry 30 (1991) 9686-9697
14. Muzammil S., et al. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations. J. Virol. 81 (2007) 5144-5154
15. Schon A., et al. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 45 (2006) 10973-10980
16. Ababou A., and Ladbury J.E. Survey of the year 2005: literature on applications of isothermal titration calorimetry. J. Mol. Recognit. 20 (2007) 4-14
17. Muralidhara B.K., and Halpert J.R. Thermodynamics of ligand binding to P450 2B4 and P450eryF studied by isothermal titration calorimetry. Drug Metab. Rev. 39 (2007) 539-556
18. Wiseman T., et al. Rapid measurement of binding constants and heats of binding using a new titration calorimeter. Anal. Biochem. 179 (1989) 131-135
19. Holdgate G.A. Making cool drugs hot: isothermal titration calorimetry as a tool to study binding energetics. BioTechniques 31 (2001) 164-166
20. Ladbury J.E. Isothermal titration calorimetry: application to structure-based drug design. Thermochem. Acta 380 (2001) 209-215
21. Brandts J.M., et al. ITC-derived binding constants: using microgram quantities of protein. In: Cooper M. (Ed). Label-Free Biosensors: Techniques and Applications (2007), Cambridge University Press
22. Lafont V., et al. Compensating enthalpic and entropic changes hinder binding affinity optimization. Chem. Biol. Drug Des. 69 (2007) 413-422
23. Lumry R., and Rajender S. Enthalpy-entropy compensation phenomena in water solutions of proteins and small molecules: a ubiquitous property of water. Biopolymers 9 (1970) 1125-1227
24. Eftink M.R., et al. Enthalpy-entropy compensation and heat capacity changes for protein-ligand interactions: general thermodynamic models and data for the binding of nucleotides to ribonuclease A. Biochemistry 22 (1983) 3884-3896
25. Cooper A., et al. Heat does not come in different colours: entropy-enthalpy compensation, free energy windows, quantum confinement, pressure perturbation calorimetry, solvation and the multiple causes of heat capacity effects in biomolecular interactions. Biophys. Chem. 93 (2001) 215-230
26. Sharp K. Entropy-enthalpy compensation: fact or artifact?. Protein Sci. 10 (2001) 661-667
27. Starikov E.B., and Norden B. Enthalpy-entropy compensation: a phantom or something useful?. J. Phys. Chem. B 111 (2007) 14431-14435
28. Bai Y., et al. Protein stability parameters measured by hydrogen exchange. Proteins 20 (1994) 4-14
29. Luque I., and Freire E. The structural stability of binding sites. Consequences for binding affinity and cooperativity. Proteins 4 (2000) 63-71
30. Ward W.H., et al. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 38 (1999) 12514-12525